|
CAUTION IS ADVISED SINCE CO-ADMINISTRATION OF DRUGS METABOLIZED BY CYTOCHROME P450 SYSTEM AND MACROLIDE ANTIBIOIC IS ASSOCIATED WITH ELEVATION IN TERFENADINE SERUM LEVELS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DISOPYRAMIDE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DIVALPROEX
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CO-ADMINISTRATON PRODUCED A 22% INCREASE IN THE CMAX OF AZITHROMYCIN
|
CAUTION IS ADVISED SINCE CO-ADMINISTRATION OF DRUGS METABOLIZED BY CYTOCHROME P450 SYSTEM AND MACROLIDE ANTIBIOIC IS ASSOCIATED WITH ELEVATION IN PHENYTOIN SERUM LEVELS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION WITH ERYTHROMYCIN AND OTHER MACROLIDE ANTIBIOTICS MAY INCREASE DIGOXIN ABSORPTION IN PATIENTS WHO INACTIVATE DIGOXIN BY BACTERIAL METABOLISM IN THE LOWER INTESTINE, SO THAT DIGITALIS INTOXICATION MAY RESULT
|
CO-ADMINISTRATION WITH ERYTHROMYCIN AND OTHER MACROLIDE ANTIBIOTICS MAY INCREASE DIGOXIN ABSORPTION IN PATIENTS WHO INACTIVATE DIGOXIN BY BACTERIAL METABOLISM IN THE LOWER INTESTINE, SO THAT DIGITALIS INTOXICATION MAY RESULT
|
CONCURRENT USE WITH ASTEMIZOLE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CARBAMAZEPINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF TACROLIMUS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
ALUMINIUM AND MAGNESIUM-CONTAINING ANTACIDS REDUCE THE PEAK SERUM LEVELS [RATE] BUT NOT THE AUC [EXTENT] OF AZITHROMYCIN ABSORPTION ; SIMULTANEOUS ADMINISTRATION SHOULD BE AVOIDED
|
ALUMINIUM AND MAGNESIUM-CONTAINING ANTACIDS REDUCE THE PEAK SERUM LEVELS [RATE] BUT NOT THE AUC [EXTENT] OF AZITHROMYCIN ABSORPTION ; SIMULTANEOUS ADMINISTRATION SHOULD BE AVOIDED
|
INCREASED CHANCES OF PROLONGED QT INTERVAL
|
CAUTION IS ADVISED SINCE MACROLIDE ANTIBIOTICS AND ERGOTAMINE CO-ADMINISTRATION IS ASSOCIATED WITH ACUTE ERGOT TOXICITY
|
CAUTION IS ADVISED SINCE MACROLIDE ANTIBIOTICS AND ERGOTAMINE CO-ADMINISTRATION IS ASSOCIATED WITH ACUTE ERGOT TOXICITY
|
CAUTION IS ADVISED SINCE MACROLIDE ANTIBIOTICS AND ERGOTAMINE CO-ADMINISTRATION IS ASSOCIATED WITH ACUTE ERGOT TOXICITY
|
CAUTION IS ADVISED SINCE MACROLIDE ANTIBIOTICS AND ERGOTAMINE CO-ADMINISTRATION IS ASSOCIATED WITH ACUTE ERGOT TOXICITY
|
CAUTION IS ADVISED SINCE MACROLIDE ANTIBIOTICS AND ERGOTAMINE CO-ADMINISTRATION IS ASSOCIATED WITH ACUTE ERGOT TOXICITY
|
CAUTION IS ADVISED SINCE MACROLIDE ANTIBIOTICS AND ERGOTAMINE CO-ADMINISTRATION IS ASSOCIATED WITH ACUTE ERGOT TOXICITY
|
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF BROMOCRIPTINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CYCLOSPORINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF PHENYTOIN
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|